SAGE PRO

Home / Research / Godrej Consumer Products Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Godrej Consumer Products Limited — Q2 FY27 Results Analysis

Consolidated Q2 sales total ₹4,396 crore

Published · Quarter Q2 FY27 · GODREJCP

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Q2 revenue by geography

Standalone India₹2,631 crore
Indonesia₹538 crore
Africa/USA/ME₹1,069 crore
LatAm/Others₹297 crore

https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf

CHART 2

Reported revenue growth

India13%
Indonesia20%
Africa/USA/ME40%
LatAm/Others43%

https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf

CHART 3

Constant currency growth

Indonesia20%
Africa/USA/ME23%
LatAm/Others28%

https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf

CHART 4

Underlying volume growth

Consolidated8%
Standalone7%

https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Consolidated Q2 sales total ₹4,396 crore

India remains the largest market

Watch: Track organic demand

RESEARCH INSIGHT

International sales growth is faster

Currency adds to reported growth

Watch: Compare constant currency

RESEARCH INSIGHT

Translation affects Africa and Latin America

Underlying growth is lower than headline

Watch: Monitor currency-adjusted demand

RESEARCH INSIGHT

Volume growth is healthy

Price and currency also affect sales

Watch: Track next quarter

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Godrej Consumer Products (GODREJCP) | Q2 FY27 | Quarter ended 30 September 2026 | Consolidated results, with standalone and geography metrics separately labelled

Investment stance: WATCH. Godrej Consumer Products grew Q2 sales by 19% and reported net profit by 14%, helped by healthy underlying demand in India, Indonesia and Africa. But EBITDA grew only 12%, showing that commodity costs and investment in the business absorbed part of the sales growth. The investment case depends on sustained volume growth and a recovery in operating margins, rather than price-led sales alone. [S1][S2]

Q2 FY27 measureValueBasis
Consolidated net sales₹4,396 croreUp 19% year on year
Consolidated underlying volume growth8%Management measure
Consolidated constant-currency sales growth15%Excludes currency translation
Consolidated EBITDA growth12%Year on year
Consolidated operating EBITDA margin18.7%Presentation's adjusted segment-margin basis
Reported consolidated net profit₹523 croreVersus ₹459 crore
Net profit without exceptional/one-off items₹532 croreVersus ₹487 crore
Standalone sales₹2,631 croreUp 13% year on year

The reported profit and profit without exceptional items are not interchangeable. The presentation reconciles ₹523 crore reported profit to ₹532 crore excluding selected items, compared with ₹459 crore and ₹487 crore respectively a year earlier. Its EBITDA margin presentation adjusts business support charges, royalty and technical fees for geographic comparability. [S2]

Six decision takeaways

  • Consolidated sales reached ₹4,396 crore, up 19%, with 8% underlying volume growth. [S1][S2]
  • Constant-currency sales growth was 15%, lower than reported 19% growth, so foreign exchange contributed to the reported rate. [S2]
  • EBITDA grew 12%, less than sales, amid significant commodity inflation. [S1][S2]
  • Standalone India sales were ₹2,631 crore, up 13%, with 7% underlying volume growth. [S1][S2]
  • Africa, USA and Middle East sales reached ₹1,069 crore, up 40% reported and 23% constant currency. [S2]
  • Consolidated reported PAT rose to ₹523 crore from ₹459 crore; adjusted-for-listed-items profit was ₹532 crore from ₹487 crore. [S2]

What to watch next: India's home-care demand and pricing, Indonesia volume momentum, Africa's currency-adjusted performance and how quickly margin pressure from commodities eases. No share-price target is assigned without a current market price and comparable valuation inputs.

Chapter 1 — What drives the investment decision

Godrej Consumer Products sells household and personal-care products across India and international markets. Its businesses include home care, personal care and country-specific consumer brands. This is a branded consumer business: pricing power, distribution reach, product relevance and advertising efficiency determine whether revenue growth becomes sustainable profit. [S1][S2]

The most attractive feature of the Q2 result is the combination of underlying volume growth and broad geographic participation. Sales growth can be misleading when driven by price increases or currency translation alone; 8% consolidated volume growth suggests a meaningful increase in product demand. But the gap between 19% revenue growth and 12% EBITDA growth shows that not all incremental sales retained their former margin. [S2]

Investors should value the domestic franchise and international businesses on their respective earnings durability. India's consumer categories are exposed to monsoon, rural demand and competitive pricing. International businesses add growth but also currency and local execution risks. The presentation gives enough evidence to compare these engines without assuming they all have the same margin. [S1][S2]

Decision tests

  • Require volume growth to remain healthy as commodity costs and pricing change. [S1]
  • Separate reported foreign growth from constant-currency growth. [S2]
  • Compare India and overseas margins on the same adjusted presentation basis. [S2]
  • Look for profit conversion, not only revenue and market-share gains.

Chapter 2 — Financial results, margins and earnings quality

The group reported ₹4,396 crore Q2 sales and 19% year-on-year growth. Constant-currency growth was 15%, while underlying volume growth was 8%. EBITDA grew 12%. These measures tell different parts of the story: volumes reflect consumer demand, constant-currency sales reflect business growth excluding translation, and EBITDA captures operating earnings after business costs. [S1][S2]

The presentation gives a consolidated operating EBITDA margin of 18.7% after specified adjustments for business support charges, royalty and technical fees. Standalone India was 21.0%, Indonesia 19.3%, Africa/USA/Middle East 15.0%, and Latin America/Others 0.9%. These geography margins should not be averaged without revenue weights or substituted for statutory consolidated profit. [S2]

Reported net profit increased from ₹459 crore to ₹523 crore. The company's reconciliation adds a net ₹9 crore of exceptional and one-off adjustments to Q2 FY27 reported profit to reach ₹532 crore. The adjustments include negative ₹11 crore of restructuring-cost adjustment and positive ₹20 crore relating to acquisition costs and other items, including litigation. For Q2 FY26, reported ₹459 crore becomes ₹487 crore after an ₹8 crore restructuring adjustment and ₹20 crore other adjustment. [S2]

The acquisition-related ₹20 crore item includes a change in fair valuation of contingent consideration for the Muuchstac brand following higher revenue than previously expected. This is an accounting adjustment tied to acquisition terms, not an additional ₹20 crore of consumer sales. The distinction matters when comparing recurring profitability. [S2]

Financial interpretation

  • Reported PAT growth is about 14%, while profit excluding specified items rose about 9%; neither should silently replace the other. [S2]
  • The adjusted geographic margin series is useful for mix analysis but is not an audited cash-flow margin. [S2]
  • EBITDA growth below sales growth makes pricing and raw-material costs the central next-quarter test. [S1][S2]
  • Currency translation explains part of the gap between reported and constant-currency growth. [S2]

Chapter 3 — India categories and international economics

Standalone India generated ₹2,631 crore sales, up 13% with 7% underlying volume growth. Management estimated that a trade-inventory correction reduced the quarter's growth by about 150 basis points (1.5 percentage points). That correction reflects distributors carrying healthier inventory levels, rather than a simple change in final consumer demand. It can temporarily affect shipments even if retail demand remains intact. [S1][S2]

Within standalone India, Home Care generated ₹1,329 crore, up 19%, while Personal Care generated ₹1,303 crore, up 8%. The two rounded categories total ₹2,632 crore versus the ₹2,631 crore standalone figure, a minor rounding difference. Management highlighted household-insecticide market-share gains despite weaker monsoon conditions and strong air-freshener demand. [S1][S2]

Indonesia sales reached ₹538 crore, up 20% both reported and in constant currency. The similar rates indicate little translation difference in this presentation's comparison. The country's operating EBITDA margin was 19.3%, and EBITDA grew 12%. Volume and product mix remain important because sales growth exceeded operating profit growth. [S2]

Africa, USA and Middle East generated ₹1,069 crore sales, up 40% reported and 23% constant currency. The large difference makes currency translation particularly relevant. Its operating EBITDA margin was 15.0%, and EBITDA grew 43% on the presentation's adjusted geographic basis. The profit growth is encouraging, but investors should not mistake currency-driven sales for recurring unit-volume growth. [S2]

Latin America and Others contributed ₹297 crore, with 43% reported and 28% constant-currency growth, but the presentation shows only a 0.9% operating EBITDA margin and an 85% decline in EBITDA. This is the clearest geographic warning: strong sales growth can coexist with weak earnings economics. [S2]

Business takeaways

  • India's home care grew faster than personal care, affecting category mix. [S2]
  • Indonesia's 20% sales growth requires continued operating-margin support. [S2]
  • Africa's 40% reported growth should be assessed against 23% constant-currency growth. [S2]
  • Latin America/Others needs margin recovery, not just more sales. [S2]

Chapter 4 — Pricing, execution and analyst questions

Management discussed commodity inflation, particularly its effect on soaps and liquid detergents. It said calibrated pricing actions and cost savings would be used to protect margins while maintaining investment behind growth categories. A pricing action can help gross profit, but it can also test consumer demand if competitors do not follow or shoppers trade down. [S1]

The company retained its FY27 outlook for high-single-digit standalone underlying volume growth and double-digit consolidated revenue and EBITDA growth. These are management targets, not completed full-year results. The Q2 standalone volume rate of 7% is consistent with a high-single-digit ambition, but one quarter cannot establish the full-year outcome. [S1]

Analysts asked about improvements in digital advertising capability, execution discipline and household-insecticide product communication. Management described a programme of changes to advertising and sales execution. The investment test is whether those changes improve market share and product sales without requiring disproportionate spending. [S1]

Management also described household-insecticide market-share gains despite subdued monsoon conditions. This matters because weather can affect demand for insect-control products. Stronger market share in a difficult season could signal better product competitiveness, but investors should verify whether it persists when weather and competitive promotions change. [S1][S2]

Execution questions

  • Do price increases restore margins without reducing unit volumes? [S1]
  • Does home-care market-share improvement persist beyond the quarter? [S1][S2]
  • Is the India inventory correction temporary, or does it signal slower retailer offtake? [S1]
  • Does international growth produce cash earnings after currency and local operating costs?

Chapter 5 — Cash, working capital and capital allocation

Consumer-products companies typically need inventory, manufacturing capacity, distribution and brand investment. Godrej's reported 8% underlying volume growth increases the need to manage those resources efficiently. Yet the Q2 excerpts selected for this report do not provide a complete consolidated operating cash-flow statement or capital-expenditure bridge, so EBITDA should not be presented as free cash flow. [S1][S2]

The India trade-inventory correction is financially relevant. Management estimated a roughly 150-basis-point growth effect from reducing channel inventory. Cleaner distributor stock can reduce the risk of future returns or promotional discounting, but it may also temporarily lower company shipments. The next test is whether retail sales continue while channel inventory remains controlled. [S1]

Acquisition-related contingent consideration is another capital-allocation issue. The presentation identifies a ₹20 crore fair-value adjustment linked to the Muuchstac acquisition. Such an item can affect reported profit without representing a current-quarter cash operating expense. Investors should keep acquisition accounting separate from the profitability of selling consumer products. [S2]

The right capital-allocation questions are practical: are advertising and product launches improving sales productivity, is inventory aligned with consumer offtake, and do international businesses generate adequate cash after local costs? The evidence supports these questions but not a precise cash-return or debt-payback estimate.

Capital checkpoints

  • Compare operating cash flow with EBITDA when the complete cash-flow statement is available.
  • Check inventory and receivables after the standalone trade correction. [S1]
  • Separate brand acquisition adjustments from normal selling costs. [S2]
  • Review advertising efficiency alongside home-care and personal-care growth.

Chapter 6 — Bull, base and bear outcomes

Bull case — volume growth and pricing restore operating leverage. India retains healthy underlying volume growth, home care maintains market-share gains, and measured pricing offsets commodity inflation. Indonesia continues to grow without margin deterioration, while Africa's underlying growth translates into cash profit. Consolidated EBITDA then has scope to grow faster than revenue. Confirmation would require an improved operating margin and consistent volume growth. [S1][S2]

Base case — sales grow faster than profit for a while. Consumer demand stays healthy, but commodity costs and investment in advertising limit near-term margin expansion. Currency translation continues to affect reported international growth, and the company balances price changes against consumer affordability. The business remains profitable, though the earnings multiple investors can justify depends on margin recovery.

Bear case — costs and execution erode the growth premium. Input costs stay high, price increases reduce volumes, or competitors take share. Weak weather or distribution changes hurt home-care demand, while Latin America remains low margin. International currency movements make headline growth look better than the underlying earnings trend. Strong revenue growth would then be a poor guide to shareholder returns.

Falsifiers

  • Consolidated underlying volume growth falls materially below Q2's 8% while prices rise. [S2]
  • EBITDA growth remains below sales growth despite cost-saving actions. [S1][S2]
  • Standalone home care loses its 19% growth momentum. [S2]
  • Africa's 23% constant-currency growth does not translate into operating profit. [S2]
  • Latin America/Others remains near a 0.9% operating margin despite rapid sales growth. [S2]

Chapter 7 — Quarterly investor action plan

Action: WATCH for margin recovery alongside durable consumer demand. Godrej's Q2 result shows meaningful growth across several markets. The next quarter needs to show whether pricing, product mix and cost control can convert that growth into a stronger profit trajectory.

Monitoring itemQ2 FY27 baselineNext decision test
Consolidated sales₹4,396 croreVolume and constant-currency growth
Consolidated underlying volume8%Sustained consumer demand
Consolidated EBITDA growth12%Catch-up with 19% sales growth
Reported PAT₹523 croreProfit conversion
PAT excluding selected items₹532 croreRepeatable earnings
Standalone India sales₹2,631 croreInventory correction and volume
Home Care₹1,329 croreMarket-share gains
Personal Care₹1,303 crorePricing and category mix
Indonesia₹538 croreMargin alongside growth
Africa/USA/Middle East₹1,069 croreConstant-currency growth and profit
Latin America/Others0.9% adjusted EBITDA marginMeaningful margin recovery

Next-quarter investor checklist

  • Track consolidated underlying volume against 8%, not just reported sales growth. [S2]
  • Compare 19% sales growth with 12% EBITDA growth and test for margin improvement. [S2]
  • Separate reported and constant-currency growth in Africa and Latin America. [S2]
  • Review soaps and liquid-detergent pricing against input costs and unit demand. [S1]
  • Check whether the standalone trade-inventory correction has ended. [S1]
  • Compare reported PAT with profit excluding the specifically disclosed exceptional items. [S2]

Specific limitations: The presentation provides adjusted geography operating EBITDA margins and a clear reported-to-exceptional-item PAT bridge, but the excerpts do not establish complete consolidated cash flow, current valuation inputs or a cash-based return on acquisition spending. The geography margin figures are adjusted for specified intercompany support and technical charges; they should not be presented as standalone statutory margins.

Original issuer and exchange filings

All financial amounts are ₹ crore unless stated otherwise. Reporting bases and management guidance are identified in context.

Additional company evidence

CHART 5

Reported PAT

Q2 FY26₹459 crore
Q2 FY27₹523 crore

https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf

CHART 6

PAT excluding listed items

Q2 FY26₹487 crore
Q2 FY27₹532 crore

https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf

CHART 7

Q2 FY27 PAT basis

Reported₹523 crore
Without listed items₹532 crore

https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf

CHART 8

Standalone India category revenue

Home Care₹1,329 crore
Personal Care₹1,303 crore

https://www.bseindia.com/xml-data/corpfiling/AttachLive/8bf1e6fa-d1b4-422f-bf06-7cdd37877e69.pdf

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure
  2. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.